Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet's disease

Rheumatology

Volumn 50, Issue 10, 2011, Pages 1849-1859

  Macey, Marion ^a   Hagi Pavli, Eleni ^b   Stewart, Joanne ^b   Wallace, Graham R ^c   Stanford, Miles ^d   Shirlaw, Penelope ^e   Fortune, Farida ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anti coagulant; Beh et's disease; Cell surface molecules; Disease activity; Flow cytometry; Inflammation; Molecular stability; Tripotassium ethylenediaminetetra acetic acid (K3EDTA) plus citrate theophylline adenosinedipyridamole (CTAD)

Indexed keywords

CD11B ANTIGEN; PADGEM PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN EXPRESSION; ARTICLE; BEHCET DISEASE; BLOOD SAMPLING; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADULT; AGE FACTORS; AGED; ANTIGENS, CD11B; BEHCET SYNDROME; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; P-SELECTIN; PLATELET ACTIVATION; SEX FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 80053166659     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker177     Document Type: Article

References (55)

1. Fortune F. Can you catch Behcet's disease? J Lab Clin Med 2003;141:5-6.
2. Marshall SE. Behcet's disease. Best Pract Res Clin Rheumatol 2004;18:291-311.
3. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335: 1078-80.
4. Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther 2003;5:139-46.
5. Yazici H, Yurdakul S, Hamuryudan V. Behcet's syndrome. Curr Opin Rheumatol 1999;11:53-7.
6. Al-Otaibi LM, Porter SR, Poate TW. Behcet's disease: a review. J Dent Res 2005;84:209-22.
7. Seyahi E, Fresko I, Melikoglu M, Yazici H. The management of Behcet's syndrome. Acta Reumatol Port 2006;31:125-31.
8. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behcet's syndrome. Drugs 1991;42:796-804.
9. Yazici H, Ozyazgan Y. Medical management of Behcet's syndrome. Dev Ophthalmol 1999;31:118-31.
10. Hatemi G, Silman A, Bang D et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 2009;68:1528-34.
11. Russell AI, Lawson WA, Haskard DO. Potential new therapeutic options in Behcet's syndrome. BioDrugs 2001; 15:25-35.
12. Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003;82:60-76.
13. Bang DS, Oh SH, Lee KH, Lee ES, Lee SN. Influence of sex on patients with Behcet's disease in Korea. J Korean Med Sci 2003;18:231-5.
14. Ames PR, Steuer A, Pap A, Denman AM. Thrombosis in Behcet's disease: a retrospective survey from a single UK centre. Rheumatology 2001;40:652-5.
15. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010;30:2357-61.
16. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol 2006;81:753-9.
17. Gironella M, Molla M, Salas A et al. The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice. J Leukoc Biol 2002;72:56-64.
18. Boilard E, Nigrovic PA, Larabee K et al. Platelets amplify inflammation in arthritis via collagendependent microparticle production. Science 2010;327: 580-3.
19. Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Ciccia F, Giardina E. Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behcet's disease. Clin Exp Rheumatol 2000;18:495-8.
20. Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995;132:901-7.
21. Kacmaz RO, Kempen JH, Newcomb C et al. Ocular inflammation in Behcet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008;146:828-36.
22. Macey M, McCarthy D, Azam U, Milne T, Golledge P, Newland A. Ethylenediaminetetraacetic acid plus citrate-theophylline-adenosine-dipyridamole (EDTA-CTAD): a novel anticoagulant for the flow cytometric assessment of platelet and neutrophil activation ex vivo in whole blood. Cytometry B Clin Cytom 2003;51:30-40.
23. Macey MG, Enniks N, Bevan S. Flow cytometric analysis of microparticle phenotype and their role in thrombin generation. Cytometry B Clin Cytom 2011;80: 57-63.
24. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 2003;42:346-51.
25. Alpsoy E, Donmez L, Onder M et al. Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study. Br J Dermatol 2007;157:901-6.
26. Yazici H, Tuzun Y, Tanman AB et al. Male patients with Behcet's syndrome have stronger pathergy reactions. Clin Exp Rheumatol 1985;3:137-41.
27. Yazici H, Tuzun Y, Pazarli H et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis 1984;43:783-9.
28. Yapislar H, Aydogan S, Borlu M, Ascioglu O. Decreased nitric oxide and increased platelet aggregation levels in patients with Behcet's disease. Thromb Res 2007;119: 461-5.
29. Nakano H, Oka H, Matsuda T et al. Spontaneous platelet aggregation in patients with Behcet's disease by using laser-light scattering aggregometer. Adv Exp Med Biol 2003;528:437-41.
30. Turkoz Y, Evereklioglu C, Ozkiris A et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behcet's syndrome. Mediators Inflamm 2005;4:237-41.
31. Akar S, Ozcan MA, Ates H et al. Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease. Clin Appl Thromb Hemost 2006;12: 451-7.
32. Golanski J, Pietrucha T, Baj Z, Greger J, Watala C. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. Thromb Res 1996;83: 199-216.
33. Hickerson DH, Bode AP. Flow cytometry of platelets for clinical analysis. Hematol Oncol Clin North Am 2002;16: 421-54.
34. McCarthy DA, Macey MG, Allen PD. A simple, novel, procedure for monitoring membrane scrambling and permeability in microparticles, platelets, and leukocytes in whole blood samples. Exp Hematol 2008;36: 909-21.
35. Martinez M, Ricart JM, Ruiz-Aja S et al. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behcet's disease: are they related to thrombotic events? Pathophysiol Haemost Thromb 2007;36:18-22.
36. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005;288:H1004-9.
37. Ehrlich GE. Vasculitis in Behcet's disease. Int Rev Immunol 1997;14:81-8.
38. Wang Y, Sakuma M, Chen Z et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005;112:2993-3000.
39. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999;341:1284-91.
40. Carletto A, Pacor ML, Biasi D et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 1997;24: 1332-6.
41. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behcet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49:247-55.
42. Mege JL, Dilsen N, Sanguedolce V et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
43. Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease: correlations with disease activity and severity. Isr J Med Sci 1995;31:345-8.
44. Triolo G, Accardo-Palumbo A, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behcet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999;91:330-7.
45. Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis 1996;55:128-\33.
46. Fortunati E, Kazemier KM, Grutters JC, Koenderman L, Van den Bosch JM. Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. Clin Exp Immunol 2009;155: 559-66.
47. Wallace GR, Kondeatis E, Vaughan RW et al. IL-10 genotype analysis in patients with Behcet's disease. Hum Immunol 2007;68:122-7.
48. Remmers EF, Cosan F, Kirino Y et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010;42:698-702.
49. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115: 3378-84.
50. May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008;28:s5-10.
51. Palabrica T, Lobb R, Furie BC et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359:848-51.
52. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001;86:746-56.
53. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999;81:1-7.
54. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.
55. Curnow SJ, Pryce K, Modi N et al. Serum cytokine profiles in Behcet's disease: is there a role for IL-15 in pathogenesis? Immunol Lett 2008;121:7-12.